Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

This quarterly report represents an earnings surprise of 39.13%. A quarter ago, it was expected that this drug developer would post earnings of $0.21 per share when it actually produced earnings of $0.25, delivering a surprise of 19.05%. Corcept, which belongs to the Zacks Medical - Drugs industry, posted revenues of $163.8 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 6.41%. This compares to year-ago revenues of $117.72 million. The company has topped consensus revenue ...